Disclosure Of First-Time Adoption [Text Block]

BerGenBio - Filing #2542730

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
127,476,000 NOK
189,234,000 NOK
854,000 NOK
268,869,000 NOK
46,987,000 NOK
88,498,000 NOK
35,780,000 NOK
0 NOK
8,866,000 NOK
43,852,000 NOK
0 NOK
40,386,000 NOK
384,426,000 NOK
335,195,000 NOK
8,846,000 NOK
Comprehensive income
189,234,000 NOK
189,234,000 NOK
0 NOK
0 NOK
0 NOK
0 NOK
302,606,000 NOK
0 NOK
302,606,000 NOK
0 NOK
Profit (loss)
190,401,000 NOK
190,401,000 NOK
0 NOK
0 NOK
0 NOK
0 NOK
302,122,000 NOK
0 NOK
302,122,000 NOK
0 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.